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Abstract
Amyloidosis is a pathological condition which consists on the accumulation of 
fibrillar proteins. This disease is characterized by extracellular amyloid deposits 
with a clinical variability depending on the affected tissue. Histopathological evi-
dence indicates that diabetes mellitus type 2 (DM2) induces dementia development, 
specifically Alzheimer’s disease (AD). It has been demonstrated in animal subjects 
that there is a possibility that aberrant signaling of insulin is a key factor in the 
induction of the pathology of AD. Recently, there has been newly emerged evidence 
regarding the relationship between the pathogenesis of Parkinson’s disease (PD) 
and insulin resistance. On another note, the importance of the amyloid deposits in 
the patients’ pancreas with DM2 was evidenced by the discovery of islets of amyloid 
polypeptide. This has generated interest in the search of the etiopathogenic role of 
DM2 in the carbohydrates’ metabolism. Finally, it is important to consider DM2 as 
a risk factor essential for the formation of deposits of amyloid-β in patients’ brains 
with dementia.
Keywords: diabetes mellitus, insulin resistance, β-amyloid, dementia,  
Alzheimer’s disease, Parkinson’s disease
1. Introduction
Dementia has become a worldwide public health issue that currently affects 50 
million people. The impact of this disease not only affects the patient himself but 
also the family and caretaker. This neurodegenerative disorder is characterized by 
the loss of mental faculties in a progressive and irreversible way which includes 
language alterations, learning and memory, as well as loss of ethical judgment and 
social behavior.
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Alzheimer’s disease is the main cause of dementia, following vascular dementia, 
senil dementia, frontotemporal dementia, and even Parkinson’s disease (P). Age is 
still the main risk factor to suffer from dementia, even though it is a multifactorial 
disorder. Smoking, alcoholism, lack of interest in education, and obesity are factors 
that can increase the risk of developing dementia in an old age [1].
Currently, obesity is another worldwide public health issue. According to the 
World Health Organization (WHO), the majority of the population lives in coun-
tries where overweight and obesity are the cause of more deaths than malnutrition. 
At the same time, obesity is one of the causes of diabetes mellitus (DM) which is a 
chronic disease derived from a failure in the pancreas to produce insulin, necessary 
hormone to process glucose [2].
Studies suggest that insulin is related with the formation of amyloid plaques 
which are histopathological structures, characteristics of some dementias such as 
Alzheimer’s disease (AD) [3]. For this reason, in recent years, DM has been consid-
ered, specifically diabetes mellitus type 2 (DM2, in which the organism is unable to 
use insulin), as an important risk factor for the development of dementia. In this 
chapter, general data about DM and dementias, as well as the importance of DM in 
the formation of amyloid aggregates which converts it in a risk factor for AD and 
Parkinson’s disease (PD), will be discussed.
2. Amyloidosis
Amyloidosis is a chronic disease that is characterized by the extracellular depos-
its of insoluble proteins in one or many organs (systematic amyloidosis). Such dis-
ease is due to the alteration in the metabolism of various proteins which is the origin 
of extracellular accumulation of material resistant to the digestion protein called 
amyloid fibrillar protein [4]. Generally, amyloid deposits are located in a systematic 
way. Amyloidosis can arise by itself (primary amyloidosis) or be a secondary effect 
of many infections, inflammatory disorders, or malignancies in diseases (secondary 
amyloidosis) (Table 1).
One of the most studied amyloid proteins is amyloid-β peptide (Aβ), which 
arises from the proteolictic processing (via amyloidogenic) of the precursor amy-
loid protein (APP) [5]. This peptide is added in an extracellular way and forms 
highly insoluble fibrils that give rise to the amyloid plaques which are found in 
patients’ brains with neurodegenerative diseases such as Alzheimer’s disease. 
Existing evidence has been suggested that monomers of Aβ do not generate a toxic 
environment in the brain parenchyma [6]; however, the oligomers of this peptide 
prevent the synapse and neuronal environment and generate an exacerbated 
inflammation associated with the glia and microgery favoring the production of 
Table 1. 
Amyloidosis classification.
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interleukins triggering the formation of reactive oxygen species that have been 
shown to be toxic, causing neuronal death [7].
3.  Definition, clinical characteristics, and epidemiology of diabetes 
mellitus
DM is a chronic metabolic disease characterized by hyperglycemia caused by a 
deficit of pancreas insulin production known as diabetes mellitus type 1 (DM1) or 
by insulin receptor dysfunction known as diabetes mellitus type 2 (DM2) [2]. DM 
is characterized by the presence of polyuria, polyphagia, and polydipsia. Patients 
present an unexplained weight loss; paresthesia of the extremities and foot pain 
may occur, as well as asthenia and recurrent or complicated infections. If the 
patients are not adequately treated, it can be associated with renal, visual, cardiac, 
intestinal, diabetic ketoacidosis, or diabetic coma complications, and it can lead to 
brain damage [8]. DM is currently considered a risk factor for the development of 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) [3].
In recent years, the prevalence of this disease has increased in a progressive and 
alarming way, becoming a public health problem. The National Center for Chronic 
Disease Prevention and Health Promotion estimates that in 2017, 9.4% of the United 
States population suffers from diabetes, that is, 30.3 million people, of which 21.1 
million people are diagnosed and 7.2 million people who have diabetes have not been 
diagnosed. On the other hand, the last report of the World Health Organization on 
the profiles of countries for diabetes in 2016 reports that in the United States, 3% of 
the population dies from this disease. Table 2 highlights the figures on the number 
of deaths caused by this disease in the five countries with the highest number of 
patients according to the statistics portal Statista.
*Data according to WHO 2016
**Data according to Statista 2017
Table 2. 
Cases and deaths due to diabetes mellitus in the countries with the highest prevalence.
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4. Amyloidosis’ association with diabetes mellitus
Case studies have shown a deep connection in patients who suffer from amyloidosis 
and type 2 diabetes, especially in those with pancreatic damage [9, 10]. Studies have 
focused on a neuro pancreatic hormone called islet amyloid polypeptide (IAPP) or 
amylin, secreted along with insulin by β pancreatic cells, and its possible etiology in 
type 2 diabetes [11]. IAPP functions as a glucose homeostatic regulator, but once it suf-
fers synthetic alterations, it starts to accumulate inside and outside the pancreatic cells 
resulting in apoptosis [12]. Although the specific etiology has remained unknown, 
there have been many hypotheses on what causes these pancreatic amyloid deposits. 
One of the most accepted hypotheses consists of a malfunctioning β pancreatic cell 
which is unable to correctly process amylin, resulting in the installment of amyloid 
proteins inside and outside the cells [13]. Another accepted theory indicates the genetic 
overexpression of amylin, which causes amyloid deposits, although there has not been 
a proven correlation (in humans) between high IAPP circulating levels and glucose 
intolerance [14]. It has been proved that the amino acids within the 26–29 sequence are 
a determinant factor proved in the development of amyloid deposits only in humans, 
simians, and felines, which are presumed to be the only three species to suffer from an 
amyloid deposit diabetes [9, 10, 15, 16]. It has been proved that in 9% of the diabetic 
population, there has been an identified mutation within the promoter region in the 
amyloid gene, increasing its transcription [17–19]. For years it has been proven that 
high blood glucose is not only toxic to β pancreatic cells, but it also generates an overex-
pression on the IAPP gene which contributes to pancreatic amyloid deposits, inducting 
cellular apoptosis [12]. It was never clear whether IAPP was the cause or the conse-
quence of diabetes, but once the genetic mutation in the promoter region was finally 
identified, there is still more research to be done in order to be completely certain.
5. Definition and epidemiology of dementias
Dementia is a syndrome of generalized deterioration, since it involves cognitive-
behavioral damage; is acquired, degenerative in most cases, and multi-etiological; 
and will have repercussions on the family, work, and social life of the person. 
Dementia is also characterized by a decrease in mental faculties of the individual, 
and clinical characteristics may vary depending on the neuropathological process 
of the disease and even the specific characteristics of each person. Symptoms may 
include short-term memory loss, temporary and spatial disorientation, and dif-
ficulty in communication and behavior alterations [20]. The most frequent types of 
dementia include vascular dementia, AD, and PD, although there are other forms 
of dementia such as frontotemporal dementia and dementia caused by Lewy body 
deposits. It usually affects older adults; however, it is not the result of normal aging.
Currently dementia is not considered a social priority in most countries, despite 
the increase in incidence. It is estimated that there are at least 50 million people in 
the world suffering from dementia, with 10 million new cases registered every year. 
WHO statistics indicates that it is expected that by the year 2030 and 2050, the 
figures will, respectively, increase to 76 million and 145 million cases. AD is the main 
cause of dementia, representing at least 60% of cases, with a prevalence of 10–30% in 
the population over 65 years of age [21–23]. On the other hand, PD is the second most 
common neurodegenerative disease after AD which frequently goes through a process 
of dementia. PD has a prevalence between 100 and 300/100,000 of the population 
[24], and it is expected that by 2030 the number of patients duplicates [25–27].
These numbers are alarming, and they represent a really serious situation 
that has not been given the attention and follow-up that is required, because as 
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already mentioned, it has not been a social priority for most countries yet has a 
great economic impact.
6. Diabetes mellitus as a risk factor for dementias
Dementia is a complex disorder of multifactorial etiology that results in altera-
tions in health status changes in lifestyle. It is important to identify the risk factors, 
at an early age, to prevent this disease. There are several factors related to dementia 
such as age [28], ethnic group [29], gender [30], genetic factors [31], physical activ-
ity [32], smoking, alcoholism [33], education level [34], environmental factors, and 
obesity [35, 36]. In addition, in the last decade, DM has been associated as a risk 
factor for dementia, especially DM2, which is also related to obesity.
Damage to cognitive functions has been observed in patients with DM2 compared 
to healthy patients [37, 38]. Individuals with DM2 present alterations in their atten-
tion capacity, execution, processing speed, work memory, and verbal memory [39, 
40]. Studies report a reduction of the gray matter in the frontotemporal cortex, as 
well as the decrease in glucose metabolism in patients with alterations in executive 
and memory functions [41], but it also has been associated to a white matter reduc-
tion [38]. On the other hand, the damages in verbal memory correlate with the integ-
rity of the parahippocampal gyrus [42]. In other words, DM2 represents an important 
risk factor for dementia. Interestingly, in the five main countries with a high DM 
prevalence (see Table 2), there is also a significant prevalence of dementia (Figure 1).
DM2 is the most common type of diabetes in which autoimmune antibodies 
appear to be the cause. In this type of diabetes, insulin resistance is observed, which 
limits the ability to respond to hormones, both endogenous and exogenous [43]. In 
some cases, insulin resistance is a result of a lower number or a mutation of insulin 
receptors (IR). These receptors are expressed in the central nervous system (CNS), 
in the hypothalamus, olfactory bulb, cerebral cortex, cerebellum, and hippocampus 
[44–46]. Insulin can cross the blood-brain barrier and reach its target, generat-
ing anorexic effects by activating the satiety center. This happens because insulin 
and the insulin-like growth factor-1 (IGF-1) activate PI3K causing the opening of 
ATP-dependent potassium channels (ChK*ATP), thus hyperpolarizing the neuron 
which causes it to disrupt its activity, and thus, it stimulates the secretion of the 
Figure 1. 
Dementia prevalence in the five countries with the highest diabetes mellitus prevalence in 2017. DM, diabetes 
mellitus (thousands); Dem, dementia (for every 1000).
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Figure 2. 
Pathway of insulin/IGF-1/PI3K/AKT/GSK3β in respect to the neuronal function and its effect on satiety. 
Normally, this pathway of insulin/IGF-1 begins when it activates IR and it phosphorylates to begin the 
pathway for PI3K. Once PKD activates AKT, it will inhibit the activity of GSK3β by phosphorylating in Ser9, 
which is associated to neuronal survival. On another note, PI3K provokes the opening of potassium canals, 
via PIP2, hyperpolarizing the neuron which is what conducts the activation of the satiety center. When 
there is no suitable recognition of insulin, GSK3β will not inhibit; therefore, it will act upon proteins [tau, 
amyloid-β (Aβ) y α-synuclein (α-syn)] related to the formation of aggregates [neurofibrillary tangles (NFT), 
amyloid plaques, and Lewy bodies (LB), respectively] which lead to neuronal death and are histopathological 
characteristics of diseases such as AD and PD. Also, the opening of potassium canals will not be taken care of, 
inhibiting the satiety (in the presence of insulin, back arrows; lack of insulin, red arrows).
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corticotropin-releasing hormone (CRH), which is anorexigenic and inhibits the 
secretion of neuropeptide Y, which is orexigenic. As mentioned above, insulin 
activates the PI3K/AKT/GSK3β pathway, where GSK3β is phosphorylated in Ser9 
(GSK3β-pSer9) by means of AKT; being phosphorylated at this site inactivates 
it, resulting in neuronal survival. However, when there is insulin resistance as in 
the case of DM2 or there is no insulin production (DM1), this pathway does not 
activate; therefore GSK3β will not be inhibited and will act upon proteins involved 
in neuronal death such as tau, amyloid-β, and α-synuclein. These proteins will form 
intracellular (tau) and extracellular (tau, amyloid-β, and α-synuclein) deposits, 
which are histopathological features (neurofibrillary tangles, plaques, and Lewy 
bodies) of dementias such as AD and PD (Figure 2). Neuronal death caused by the 
lack of insulin is one of the reasons why DM is a risk factor for dementia.
7.  Diabetes mellitus and amyloid-β protein pathology in Parkinson’s 
disease
Clinically, Parkinson’s disease is defined as a progressive disorder characterized 
by resting tremor, rigidity, and bradykinesia; however, there may be other manifesta-
tions less constant such as postural instability, propulsive gait, dysphagia, autonomic 
disorders, sebaceous sweating, salivation, and deteriorating superior functions that 
can lead up to dementia. This disease was described in 1817 by James Parkinson, who 
described the deficiency of dopamine in the brain of his patients in late 1950 and 
also described the treatment of this disease with L-dopa in the 1960s. Parkinson’s 
disease is the second most frequent neurodegenerative disorder. It is a motor disease 
related with the disorder of the basal ganglia specifically via nigrostriatal which is 
formed by the axons of the dopaminergic neurons of the substance compact nigra 
which innervate the corpus striatum. This structure is considered the main target 
of dopaminergic innervation due to the high density of axons it receives and its 
large size. The main symptoms of Parkinson’s disease are caused by the degenera-
tion of dopaminergic neurons via nigrostriatal [47, 48]. A pathological hallmark of 
Parkinson’s disease is the Lewy bodies (LB), eosinophilic inclusions of α-synuclein 
(α-syn) located in the neuronal soma especially in nigra substance [49]. Besides the 
(LB) there can be deposits of the protein tau (MNF) and of β-amyloid (plaques).
There is existing evidence that α-syn, tau and Aβ act in a synergistic way in the 
pathology of AD and PD [50, 51] accelerating the aggregation of each [52]. The 
presence of tau and Aβ was found in patients with PD, and the cognitive function 
was lower than healthy patients’ [53]. It has also been demonstrated that when these 
three proteins are found in high concentrations, as in PD, it generates changes in CFS 
tau levels [54], and if these patients are obese as well, they present insulin resistance 
[55, 56] even though they do not suffer from DM. These patients have deficits of 
cognitive functions. It is possible that the resistance to insulin accelerates the demen-
tial process in patients with PD, and it can lead to more serious motor symptoms.
As described before, insulin/IGF-1 activates the route PI3K/AKT/GSK3β, which, 
besides being involved in the glucose metabolism and the ingestion of food, also 
plays an important role in the learning and memory process associated with long-
term potential (LTP) in the hippocampus [57]. Apparently, insulin stabilizes the 
production of dopamine and decreases the alterations in movement in a PD model 
[58–61]. When insulin acts over IR in a suitable way, the result is neuronal survival; 
however, the lack of insulin provokes that the GSK3β will not be inactivated (when 
it is phosphorylated in Ser9 by AKT), which leads to the favoring of the formation 
of MNF, LB, and amyloid plaques (see Figure 2). These pathological structures are 
found frequently coexisting in the hippocampus and cerebral cortex in patients 
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with PD [62]. The negative regulation of GSK3β is extremely important in the 
neurodegenerative disorders such as PD [63] and even more in the function of 
α-syn, having as consequences cognitive deficits [64, 65] which include learning 
and memory alterations as well as executive functions. If this negative regulation of 
GSK3β does not happen due to the lack of insulin, then there will be a tau phosphor-
ylation increase which will favor the accumulation of α-syn amyloid. These aggre-
gates of α-syn have a positive feedback over the accumulation of phosphorylated 
tau and facilitate the formation of Aβ deposits. The accumulation of aβ and α-syn 
(amyloid) activates GSK3β, even though α-syn does so by inhibiting the formation 
of GSK3β-pSer9 (Figure 3).
It is possible that patients with DM-PD deteriorate rapidly due to the favor-
ing of the accumulation of Aβ due to the lack of insulin, since this could generate 
more oxidative stress and thereby damage dopaminergic neurons. However, more 
studies are needed regarding the interaction between Aβ and α-syn in the demential 
process of PD caused by the failure in recognition of insulin such as in DM2.
8.  Diabetes mellitus and amylin and amyloid-β protein pathologies in 
Alzheimer’s disease
AD is one of the most prevalent dementias in older people and is characterized 
by the progressive loss of memory and deterioration of cognitive functions such as 
judgment and behavior [66]. AD develops through mutations in the chromosomes 
(presenilin 2), chromosome 14 (presenilin 1) and chromosome 21 (PPA) [67]. Only 
5% of patients with AD associate to this genetic factor. It has an early appearance 
in people around 45 years old; however, the most common form of appearance of 
this neurodegenerative disease is “sporadic” where there are no mutations and it 
develops in people around 65 years [68]. There is still doubt regarding the genesis 
of sporadic AD; risk factors that can lead to the development of AD have been 
described. One of these risk factors is aging and poor eating habits where it involves 
ingesting large quantities of fat and sugar. Therefore, obesity is a risk factor for 
diabetes mellitus type 2.
Figure 3. 
GSK3β activation regulated by synergistic action of α-synuclein (α-syn), phosphorylated tau (pTau), and 
β-amyloid (Aβ). In the presence of insulin, a GSK3β inhibition occurs that has as a result, the improvement of 
long-term memory in the hippocampus. When there are alterations in the recognition of the insulin or there is 
simply no production, no GSK3β inhibitions occur which promoted the augmentation of α-sy, pTau, and Aβ 
aggregates which at the same time act synergistically, augmenting GSK3β activity. Therefore, cognitive deficits 
that include alterations in the learning and memory processes as well as executive functions are favored.
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Histopathologically, the brains of these patients present in great abundance 
neuritic plaques (NP) and neurofibrillary tangles. (NFT) [69, 70]. Neuritic 
plaques are constituted by extracellular deposits of the fibrillar beta-amyloid 
peptide, and associated to these, dystrophic neurites (DN), neuritic plaques 
bordered by astroglial cells and associated with the amyloid peptide, the tight 
microglial cells can be observed (Figure 4). Together, they unleash the inflam-
matory cell process observed in a brain with AD [71]. NFT are constituted by 
highly soluble filaments (paired helical filaments, PHF) inside the neuronal 
soma. The PHF are constituted by tau protein; in normal conditions, tau protein 
favors the stability to the microtubules and the organelles and vesicles along the 
axon. The genesis of PHF has been associated with posttranslational mechanisms 
of tau protein as in hyperphosphorylation and truncation. Recent studies have 
suggested that the tau protein plays a dual role in protection and toxicity upon 
the neurodegenerative process and neuronal death. The phosphorylation of the 
tau protein could be involved in processes of neuronal protection to degeneration 
Figure 4. 
Characteristic lesions of a brain with Alzheimer’s disease. (A) Neuritic plaque. Dystrophic neuritis (green 
and blue channels) are observed in the periphery of the Aβ deposit (red channel). (B) Neurofibrillary tangles 
recognized by antibodies directed against phosphorylated tau protein, in the vicinity there is a neurofibrillary 
tangle evidenced only in the red channel, the dystrophic neuritis in the periphery show different degrees of 
co-localization. (C) Neuritic plaque evidenced in the red channel, the nuclei are observed in blue color. The 
microglial cells are closely associated with the Aβ deposit (green channel). (D) Neuritic plaque in the periphery 
glial cells (blue channel) are observed. And in the channel see observed neuritic dystrophic positive tau protein. 
Double immunostaining with antibodies directed against the phosphorylated tau protein (A, B), IBA1 (C), and 
GFAP (D), counterstained with triazine red dye A-D and ToPro (C). Images taken with confocal microscope 
(SP8, Leica).
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upon the fragment of the minimal filament (92–95 amino acids culminating in 
Glu391). The process of proteolysis in the asp-421 of tau favors in the beginning 
its polymerization, and the truncation in glu391 favors the stability and insolubil-
ity of the PHF [72].
8.1 Amyloid formation is the pathological hallmark of T2D and AD
The incidence of both AD and T2D is increasing at an alarming rate at present 
and has become a major public health concern in many industrialized countries 
[73]. Many epidemiological studies have shown that diabetic individuals have a 
significantly higher risk of developing AD [74]. Recently, it has become increas-
ingly recognized that there is an overlap between the pathology of AD and vas-
cular dementia and cerebrovascular dysfunction plays a role not only in vascular 
dementia but also in AD [75]. Nevertheless, clinical observations suggest that the 
association is independent of vascular factors [76], which raises the possibility that 
diabetic conditions such as insulin resistance and hyperglycemia may affect the 
fundamental pathogenesis of AD. Many neuronal functions are affected by changes 
in the insulin signaling pathway; therefore diabetes mellitus may have an important 
role in the progression of AD ([77]; see Figure 2).
Another possible mechanism that has been involved is the amyloid deposition 
in islets composed primarily of islet amyloid polypeptide (IAPP or amylin) that is a 
common feature in T2D. IAPP amyloid deposition has been correlated with disease 
severity, reduced β-cell mass, the development of hyperglycemia, and islet inflam-
mation. Similarly, Aβ plays a central role in synaptic dysfunction and in the cogni-
tive deficiencies associated with AD pathogenesis [78]. Evidences from clinical and 
animal studies associate the pancreatic amyloid, amylin in mediating neuronal loss 
in AD, suggesting its role as a potential link between AD and T2D pathogenesis 
[79–81]. The presence of amyloid deposits in pancreas and brain has been demon-
strated in patients with T2D, which can serve as seed to increase the aggregation 
of these deposits. This suggests that pancreatic IAPP can potentiate amyloid beta 
misfolding in patients with AD [81]. Previously, de la Monte and colleges, 2008, 
reported that IAPP enters the brain, augments Aβ misfolding, and associates with 
Aβ plaques, and plasma levels correlate with AD diagnosis [82]. Interestingly, amy-
lin has been identified in human cerebrospinal fluid and brains of diabetic patients 
with vascular dementia or AD and nondiabetic patients with AD. Furthermore, 
co-localization of amylin and Aβ deposits was also observed in postmortem human 
brains [81]. Likewise, amylin deposits were observed in the temporal lobe gray 
matter in diabetic patients [79]. Therefore, the co-existence of Aβ and amylin in 
the brain suggests the potential ability of amylin to infiltrate the brain and induce 
amyloid deposition in the brain [81].
8.2  Potential mechanisms of amylin-Aβ-induced toxicity in neurons and 
pancreatic β cells
Several studies have showed that amyloid aggregates have been found to be 
associated with disruption of several cellular functions, including mitochondrial 
activity [83, 84], oxidative stress [85], receptor mediated functions [86, 87], disrup-
tion of Ca2+ homeostasis [88], and membrane depolarization and disorder [89]. 
Possibly there is a toxic interaction between Aβ and tau that together with insulin 
resistance participate in the progression of AD. Similarly, the accumulation of 
amylin in the brain and its ability to induce neurotoxicity and form “cross-seeding” 
aggregates with Aβ provide a role for this pancreatic amyloidogenic protein in 
neurodegeneration [89].
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On the other hand, it is likely that there is also a synergistic interaction between 
the accumulation of amylin in the pancreas and the insulin secretion decrease, 
which will lead to abnormalities in glucose metabolism, promoting the development 
of neurodegenerative diseases (Figure 5). It is suggested that amylin mediates neu-
rotoxicity by crossing the blood-brain barrier and binding to its receptors [90–92]. 
This leads to the hyperamulinemia of insulin resistance and to the accumulation of 
amyloid deposits in the brain.
Both in the animal models and in the clinical trials of AD, those drugs related to 
production of insulin have been observed or have focused on improving the mecha-
nisms of insulin and improving the condition of patients with cognitive impairment 
[93]. Analogues of amylin, for example, pramlintide, have been used as adjunctive 
therapy with insulin for diabetes [94] and are also being evaluated for their ability 
to prevent neurodegeneration [90, 95, 96].
9. Conclusions
The advantages of studying therapies for T2D in diseases that occur with an 
insane process are evident. However, no one has questioned whether targeted 
therapies for dementias could be useful in the treatment of T2D. Immunotherapy 
targeting Aβ has been shown to improve blood glucose by increasing sensitivity to 
insulin [97, 98]. Thus, we believe that amyloid deposits as therapeutic targets could 
be key in the treatment of dementias and alterations in glucose metabolism. But 
more studies about this issue are needed.
Figure 5. 
Association between AD and T2D. Both AD and T2D present cellular loss and abnormal deposition of Aβ, 
tau, and amylin. These aggregates have the ability to promote the accumulation of amyloid by cross-seeding 
in neurons and pancreatic cells. The aggregation of amyloid deposits is favored by the presence of aggregates 
of tau and amylin, which in turn leads to oxidative stress, mitochondrial dysfunction, inflammation, insulin 
resistances, and finally cell death.
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